Alembic Pharmaceuticals Capital Structure Change

Regulatory ApprovalAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Other Announcement

Alembic Pharmaceuticals Other Announcement

Alembic Pharmaceuticals Limited has updated its list of Key Managerial Personnel authorised to determine materiality and make stock exchange disclosures. This update follows a board meeting held on November 4, 2026.

PartnershipAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Partnership

Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.

From

DifGen Pharmaceuticals

Execution

Initial launches from FY28

Earnings Call

Alembic Pharmaceuticals Investor Presentation: Key Takeaways

Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).

Results Update

Alembic Pharmaceuticals Results Update

Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.

Value

₹2,603 Cr

Financial ResultsAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Q2 FY27 Results: Net Profit ₹335.2 Cr, Up 81.5% YoY

Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,604 Cr (+36.3% YoY) and net profit of ₹335.2 Cr (+81.5% YoY) for Q2 FY27.

Key figure

Net profit ₹335.2 Cr · +81.5% YoY

Capital Structure ChangeAegis Logistics Ltd AEGISLOG

Aegis Logistics Capital Structure Change

Aegis Logistics opened its QIP on November 11, 2026, with a floor price of Rs 1,161.85 per share. The issue size is not disclosed.

Capital Structure ChangeIndusInd Bank Ltd INDUSINDBK

IndusInd Bank Capital Structure Change

ICICI Prudential Mutual Fund net sold 1,55,98,130 IndusInd Bank shares, cutting its stake to 3.01%. The sale was in the open market, reducing the holding from 5.01%.

Capital Structure ChangeKreon Finnancial Services Ltd KREONFIN

Kreon Finnancial Services Capital Structure Change

Kreon Financial Services bought 82,503 Kairosoft AI shares (0.70%) in the open market, lifting its stake to 19.03%. This non-promoter SAST disclosure states no transaction price.

Capital Structure ChangeAtul Ltd ATUL

Atul Capital Structure Change

Atul's daily buy-back report shows 9,210 shares bought on NSE on 11 November 2026 for Rs 4.88 Crore. Cumulative buy-back stands at 57,500 shares.

Value

₹4.88 Cr

Capital Structure ChangePVV Infra Ltd PVVINFRA

PVV Infra Capital Structure Change

PVV Infra converted 1,10,74,224 partly paid rights shares to fully paid after receiving ₹4.15 Crore call money. A reminder notice for remaining partly paid shares follows.

Value

₹4.15 Cr

Capital Structure ChangeBajaj Finance Ltd BAJFINANCE

Bajaj Finance Capital Structure Change

Bajaj Finance's Special Committee opened its Rs 11,700 Crore QIP and approved the placement document on 11 November 2026. Equity shares will be issued subsequently under the shareholder-approved plan.

Value

₹11,700 Cr